References

w1 Einarson TR. Drug-related hospital admissions. Ann Pharmacother 1993;27:832-40.

w2 Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients - A meta-analysis of prospective studies. JAMA 1998;279:1200-5.

w3 Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet 2000;356:1255-9.

w4 Waller PC, Evans SJ. A model for the future conduct of pharmacovigilance. Pharmacoepidemiol Drug Saf 2003;12:17-29.

w5 van Grootheest AC, van Puijenbroek EP, de Jong-van den Berg LT. Contribution of pharmacists to the reporting of adverse drug reactions. Pharmacoepidemiol Drug Saf 2002;11:205-10.

w6 Egberts TC, Smulders M, de Koning FH, Meyboom RH, Leufkens HG. Can adverse drug reactions be detected earlier? A comparison of reports by patients and professionals. BMJ 1996;313:530-1.

w7 Derry S, Kong Loke Y, Aronson JK. Incomplete evidence: the inadequacy of databases in tracing published adverse drug reactions in clinical trials. BMC Med Res Methodol 2001;1:7.

w8. International Conference on Harmonisation. Draft consensus guideline. Pharmacovigilance planning (PvP) E2E, 2003. http://www.ich.org/ (accessed 19 Apr 2004).

w9 MHRA. Clinical Trials Directive (2001/20/EC), 2004. http://medicines.mhra.gov.uk/ourwork/licensingmeds/types/clintrialdir.htm (accessed 19 Apr 2004).

w10 Owens SR. Injection of confidence. The recent controversy in the UK has led to falling MMR vaccination rates. EMBO Rep 2002;3:406-9.

w11 Edwards A, Elwyn G, Mulley A. Explaining risks: turning numerical data into meaningful pictures. BMJ 2002;324:827-30.